Sign in Subscribe
Pharmaceutical industry

Sinovac Biotech Ltd. Investment Report Features Chinese Vaccine Maker

Strategic Insights

— 2 min read

Sinovac Biotech Ltd. (SVA), a Chinese vaccine maker, has been featured in a recent investment report by StockPreacher.com, highlighting its financial and investment analysis, analyst consensus, and pertinent industry information. The report is particularly relevant for other biotechnology companies, including Amgen Inc. (AMGN), Biogen Idec Inc. (BIIB), Genzyme Corp. (GENZ), and Gilead Sciences Inc. (GILD). Sinovac Biotech Ltd. is an emerging biotechnology company focused on developing, manufacturing, and commercializing human vaccines against infectious diseases.

The company's portfolio includes vaccines against hepatitis A, hepatitis B, and influenza viruses, with its Panflu(tm) vaccine approved for government stockpiling. The analyst notes that Sinovac Biotech Ltd.'s H1N1 vaccine has passed experts evaluation organized by SFDA, demonstrating a good safety profile and immunogenicity factors that meet the EU criterion after a single shot. The company is expected to obtain production licensure within one week.

Key Takeaways:

  • Sinovac Biotech Ltd. (SVA) is a Chinese vaccine maker focused on developing, manufacturing, and commercializing human vaccines against infectious diseases.
  • The company's portfolio includes vaccines against hepatitis A, hepatitis B, and influenza viruses, with its Panflu(tm) vaccine approved for government stockpiling.
  • The company's H1N1 vaccine has passed experts evaluation organized by SFDA, demonstrating a good safety profile and immunogenicity factors that meet the EU criterion after a single shot.
  • Sinovac Biotech Ltd. is expected to obtain production licensure within one week.
  • The company will provide Beijing with its split viron vaccine, Anflu(r), which is also hoped to provide H1N1 swine flu protection.
  • StockPreacher.com has published an investment report featuring Sinovac Biotech Ltd.
  • The report includes financial and investment analysis, analyst consensus, and pertinent industry information.
  • Sinovac Biotech Ltd. is an emerging biotechnology company that has been boosted by the news that the company was chosen as one of the four manufacturers to supply Beijing with seasonal flu vaccine for 2009.

Statistics:

  • The stock price of Sinovac Biotech Ltd. (SVA) was boosted after the company announced its H1N1 vaccine had passed experts evaluation, reaching a record high.
  • The stockhideout.com website shows that Sinovac Biotech Ltd. (SVA) is a popular stock among investors, with a dedicated discussion section.
  • The report by StockPreacher.com features the company's financial and investment analysis, analyst consensus, and pertinent industry information.
  • The company's Panflu(tm) vaccine has been approved for government stockpiling.
  • Sinovac Biotech Ltd. will provide Beijing with its split viron vaccine, Anflu(r), which is also hoped to provide H1N1 swine flu protection.

Sources:

  • StockPreacher.com (http://www.stockpreacher.com/n/SVA)
  • GlobeNewswire (http://www.globenewswire.com/)
  • StockPreacher.com Disclosure (http://www.stockpreacher.com)
  • BlueWave Advisors, LLC (http://www.stockpreacher.com)
  • Comtex SmarTrend (http://www.mysmartrend.com)
  • Comtex News Network, Inc. (http://www.comtex.com)

Read more